Dio Tree

Executive Summary

Dio Tree is an Israeli preclinical biotech developing first-in-class small-molecule inhibitors of the DIO3 enzyme, targeting high-grade serous ovarian cancer (HGSOC) and other DIO3-dependent tumors. By leveraging novel dibromomaleic anhydride scaffolds, the company aims to restore tumor-suppressive thyroid hormone activity, offering a novel therapeutic approach beyond chemotherapy and PARP inhibitors. HGSOC is an aggressive ovarian cancer subtype with high unmet need, especially in platinum-resistant patients. Dio Tree’s platform addresses a validated target with a unique chemical scaffold that could improve selectivity and safety. The company is poised to advance its lead candidate toward IND-enabling studies, with potential for significant value creation if preclinical data translate to clinical benefit.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead DIO3 Inhibitor60% success
• Q3 2026Preclinical Efficacy Data in HGSOC Models70% success
• Q2 2027Strategic Partnership or Licensing Deal40% success